After the SEAM-RA study, in patients taking MTX and ETN in sustained remission would you? #ACR20 @rheumnow

We have great options all around! Both are efficacious in biologic (TNFi) failures for RA patients. Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis Abst#0827 #ACR20 @RheumNow https://t.co/1SsL9qLJD3

• Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: M…

SEAM-RA trial Abst#0939 Combo TNF/MTX Rx -> ETN monoRx superior to MTX monoRx in sustaining remisson, simliar to staying on combo Rx. #ACR20 @RheumNow. Benefit of continuing combo: protect HACA Ab and longevity of TNFi https://t.co/Q934naKnBq

Another biosimilar Adalimumab. SB5 switch in RA, PsA & SpA N=354 No diff in effectiveness Some minor flares. Some changed dose unsure why. #ACR2020 @RheumNow @CRASCRRheum abstr#805 https://t.co/2Zb4H2jBXQ

MEASURE2 and COAST-W data stratified by TNFi inadequate responders may suggest different axSpA subset (domain?) response to TNFi vs IL17i. Dr. J. Ermann #ACR20 @RheumNow #ACRbest https://t.co/0ZcEIvkuMj

OBRI Canadian registry showed real world retention data for Tofa and TNFi are both similar, but RA pts on TNFi w/o MTX d/c drug more compared to those who stay on MTX (does not matter with Tofa if they are on MTX) Abstr#808 #ACR20 @rheumnow https://t.co/TDmV0EJTp8

• Time to Discontinuation of Tofacitinib and TNF Inhibitors in Rheumatoid Arthrit…

SEAM-RA: SDAI remission greater in pts on ETN alone vs. MTX alone; ⬆ pts in remission w/ combined tx vs. MTX alone. These may guide tx decisions re withdrawal in well-controlled RA @Rheumnow #ACR20 https://t.co/33GhuMuL3I

Never forget how far we have come in rheumatology therapeutics, in a very short period of time. Some of the original slides that Tiny Maini and Marc Feldmann used. @r_burmester giving the Phillip Hench Lecture #ACR20 @RheumNow https://t.co/YI32BX2iw8

Which Adalimumab biosimilar to use (if any)? The race is on to have 1st Ada or 2nd reimbursed/preferentially listed in US reimbursement plans & dare I say it mandatory switching like in Europe. Abstr#0798 #ACR2020 compares Abrilada & Humira in RA @RheumNow @CRASCRRheum https://t.co/AUcVZnc6Gj

FUTURE2 analysis of 78 TJC and 76 SJC scores in PsA pts treated with SEC demonstrated improvements in synovitis at Week 24 sustained over 5 years, irrespective of TNFi history & concomitant MTX use. #ABS0875 #ACR20#ACRbest @RheumNow https://t.co/U8B50PTWET https://t.co/fUK1JO10ox

• Secukinumab Provides Sustained Improvements in Subgroup Analyses of Joint Tende…

What do you think? The great debate continues... leave your thoughts in the comment section below! #ACR20 @RheumNow @LCalabreseDO @CCalabreseDO https://t.co/KwQX0XoO93

• https://twitter.com/mdwarrington/status/1324743310758563840

Year in review by @JYazdanyMD ENTRACTE trial: CV safety of TCZ vs. ETN >similar CV events >TCZ grp slightly more infections & GI perforations @RheumNow #ACR20 https://t.co/yBDeHBDB3Z

Concise, educational and useful table by @ArleneBravoMD presented by Dr. Arthur Kavanaugh in his PsA clinical trials update. Beautiful organization of targeted therapy in multiple autoimmune diseases. Bedside to Bench. @RheumNow #ACR20 https://t.co/PIvvsQWs0J

This convinces me! #TNF inhibitors vs #JAKI great debate at #ACR20 https://t.co/Xb8KkmDJ8f